How to Achieve Premium Pricing in Europe
Executive Summary
Most pharma firms deal with disparate European drug prices by attempting to retain premium pricing in friendlier markets, and exploiting loopholes as best they can elsewhere. But EU enlargement is likely to pull average prices lower still. Before long, the only way to achieve premium prices will be to present compelling health economic data justifying a product's price.